Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-06-10 4:38 pm Purchase | 2026-06-04 | 13G | QUINCE THERAPEUTICS INC NE QNCX | Integrated Core Strategies (US) LLC | 70,185 7.200% | 70,185 (New Position) | Filing History |
| 2026-05-15 4:38 pm Purchase | 2026-03-31 | 13G | QUINCE THERAPEUTICS, INC QNCX | Nantahala Capital Management, LLC | 226,415 7.520% | 198,313 (+705.69%) | Filing History |
| 2026-03-05 5:52 pm Purchase | 2026-02-28 | 13G | QUINCE THERAPEUTICS, INC QNCX | GROUP ONE TRADING LLC | 29,715 10.700% | 29,715 (New Position) | Filing History |
| 2025-11-14 4:32 pm Purchase | 2025-09-30 | 13G | QUINCE THERAPEUTICS, INC QNCX | Nantahala Capital Management, LLC | 28,102 9.990% | 4,273 (+17.93%) | Filing History |
| 2025-10-30 2:29 pm Sale | 2025-07-07 | 13G | QUINCE THERAPEUTICS, INC QNCX | Genextra S.p.A. | 0 0.000% | -14,033 (Position Closed) | Filing History |
| 2025-08-14 4:33 pm Purchase | 2025-06-30 | 13G | QUINCE THERAPEUTICS, INC QNCX | Nantahala Capital Management, LLC | 23,829 9.990% | 23,829 (New Position) | Filing History |
| 2025-04-30 4:06 pm Sale | 2025-03-31 | 13G | QUINCE THERAPEUTICS, INC QNCX | Sofinnova Capital VIII | 5,989 2.700% | -6,000 (-50.05%) | Filing History |
| 2025-02-18 1:46 pm Purchase | 2024-10-18 | 13G | QUINCE THERAPEUTICS, INC QNCX | Genextra S.p.A. | 14,033 6.490% | 1,403 (+11.11%) | Filing History |
| 2025-02-14 4:29 pm Purchase | 2024-12-31 | 13G | QUINCE THERAPEUTICS, INC QNCX | Sofinnova Capital VIII | 11,989 5.400% | 1,211 (+11.24%) | Filing History |
| 2024-11-14 4:00 pm Unchanged | 2024-09-30 | 13G | QUINCE THERAPEUTICS, INC QNCX | TANG CAPITAL MANAGEMENT LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-11-13 9:17 pm Purchase | 2021-03-04 | 13D | QUINCE THERAPEUTICS, INC QNCX | Lamond David | 22,301 10.100% | 12,056 (+117.68%) | Filing History |
| 2024-08-06 8:04 pm Sale | 2024-05-01 | 13G | QUINCE THERAPEUTICS, INC QNCX | Sofinnova Capital VIII | 10,778 4.990% | -113 (-1.04%) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | QUINCE THERAPEUTICS, INC QNCX | TANG CAPITAL PARTNERS LP | 16,100 7.500% | -2,000 (-11.05%) | Filing History |
| 2024-02-12 09:00 am Purchase | 2023-12-31 | 13G | QUINCE THERAPEUTICS, INC QNCX | Sofinnova Capital VIII | 10,891 5.100% | 10,891 (New Position) | Filing History |
| 2024-02-07 10:50 am Sale | 2023-12-31 | 13G | QUINCE THERAPEUTICS, INC QNCX | BML Investment Partners, L.P. | 0 0.000% | -9,207 (Position Closed) | Filing History |
| 2023-12-14 5:51 pm Purchase | 2023-10-20 | 13G | QUINCE THERAPEUTICS, INC QNCX | Genextra S.p.A. | 12,630 5.890% | 12,630 (New Position) | Filing History |
| 2023-07-17 11:07 am Purchase | 2023-07-06 | 13G | QUINCE THERAPEUTICS, INC QNCX | BML Investment Partners, L.P. | 9,207 5.070% | 9,207 (New Position) | Filing History |
| 2023-03-31 4:00 pm Purchase | 2023-03-21 | 13G | QUINCE THERAPEUTICS, INC QNCX | TANG CAPITAL PARTNERS LP | 18,100 9.980% | 18,100 (New Position) | Filing History |
| 2023-02-13 5:28 pm Sale | 2022-12-31 | 13G | QUINCE THERAPEUTICS, INC QNCX | EPQ LLC CTYM PS | 7,884 4.400% | -6,431 (-44.92%) | Filing History |
| 2022-07-08 12:56 pm Sale | 2022-07-11 | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital World Investors | 0 0.000% | -12,509 (Position Closed) | Filing History |